pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
Drugs
by stage
Marketed
Phase 3
Phase 2
Phase 1
Preclinical
browse
Most catalysts
Recently active
All drugs →
Companies
Patent cliff
Calendar
what
Trial readouts
PDUFA dates
Approvals
Earnings
when
Upcoming
Month grid
Recently passed
◐
Sign In
Subscribe
home
jobs
news
search
Rare Disease · news · pharmadog
← back to Rare Disease
News · Rare Disease
1,176
stories
10h
FDA Approves First Drug to Treat Neurological Symptoms of Type 3 Gaucher Disease
fda press
13h
White House pulls nomination for FDA nominee Overton
biopharma dive
14h
CTAD 2026: Biogen, AriBio lead the way in slowing cognitive decline in Alzheimer’s
biospace
15h
Merck scraps centerpiece of $2.7B ArQule buy after late-stage safety concerns
biospace
19h
Summit’s rejection, Isomorphic’s record $5B raise, obesity and Alzheimer’s in the spotlight
biospace
1d
5 acquisitions that forced Big Pharmas to co-parent
biospace
1d
White House yanks Overton nomination hours before committee vote
biospace
1d
Larbi Inc. Recalls Yellow Dock Root Because of Possible Health Risk
fda recalls
1d
Beren wins FDA approval for long-studied rare disease drug
endpoints
1d
FDA Approves First Drug Shown to Help Patients with Infantile-Onset Niemann-Pick Disease Type C Live Longer
fda press
1d
AstraZeneca, Calidi, Tempest make significant workforce cuts
biospace
1d
Vertex on the verge of ‘iconic’ evolution as key kidney disease verdict looms
biospace
1d
Scientists uncover ‘very detailed map’ of an enzyme target for rare metabolic disease
fiercebiotech
1d
NIH’s infectious disease unit has a new head at last
stat
1d
STAT+: With $173 million, new startup takes aim at sickle cell
stat
1d
STAT+: After death in gene therapy trial for a brain disease, progress is reported
stat
2d
Sellas marks 9-month survival benefit in late-stage leukemia vaccine study
fiercebiotech
2d
Serious adverse events mar robust efficacy data for Helus’ psychedelic in major depression
biospace
2d
ObesityWeek 2026: Wave outlines case for body composition–based trial design
biospace
2d
Lilly adds to buyout streak with $1.5B purchase of startup Calytrix
biopharma dive
2d
STAT+: Versant, Lilly put $100 million behind new startup aimed at solving one of gene therapy’s thorniest issues
stat
2d
Big-name investors pour $100M into DNA therapeutics developer Seawolf
biopharma dive
2d
Lilly secures another myelofibrosis option via $1.5B deal for JPM-founded Calytrix
fiercebiotech
3d
Emerging biotech hubs step up as innovation economics evolve
biospace
3d
BioSpace 40 Under 40 winners Paull, Zhang let patients with rare disease lead the way at BridgeBio
biospace
3d
Deaths, failed trials and other recent setbacks in the autoimmune space
biospace
3d
Recon: FDA rejects ivonescimab for lung cancer indication; J&J to buy eye disease biotech Ollin Biosciences for up to $3.3B
raps
5d
Argenx is spending billions to push beyond Vyvgart
endpoints
5d
AstraZeneca pulls EU filing for antibody as CHMP backs Gazyvaro in lupus
endpoints
5d
HHS pumps up to $25M into ibogaine, other psychotropic drugs on Veteran’s Day
biospace
← prev
page 1 of 40
next →